Next Article in Journal
Analysis of Predictive Values Based on Individual Risk Factors in Multi-Modality Trials
Previous Article in Journal
A Disposable Microfluidic Virus Concentration Device Based on Evaporation and Interfacial Tension
Previous Article in Special Issue
MicroRNAs as Biomarkers in Cancer
Article Menu

Export Article

Open AccessReview
Diagnostics 2013, 3(1), 170-191;

Development of MicroRNA Therapeutics for Hepatocellular Carcinoma

Department of Radiology, University of Minnesota Medical School, MMC 292 Mayo Memorial Building, 420 Delaware Street S.E., Minneapolis, MN 55455, USA
Received: 5 February 2013 / Revised: 1 March 2013 / Accepted: 11 March 2013 / Published: 15 March 2013
(This article belongs to the Special Issue Molecular Biomarkers for Cancer Targeted Therapeutics)
View Full-Text   |   Download PDF [213 KB, uploaded 15 March 2013]


Hepatocellular carcinoma (HCC) is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. Treatment options for HCC are very limited, as it is often diagnosed at a late stage. Recent studies have demonstrated that microRNAs (miRNAs), a class of non-coding RNAs, are aberrantly expressed in HCC. Some of these were shown to be functionally involved in carcinogenesis and tumor progression, suggesting that miRNAs can serve as novel molecular targets for HCC therapy. Several promising studies have recently demonstrated the therapeutic potential of miRNAs in animal models and in reducing the viral load in hepatitis C patients. In this review, these advances and strategies for modulating miRNAs for in vivo therapeutic delivery and replacement therapy are discussed. View Full-Text
Keywords: microRNA; replacement therapy; liver cancer; animal model microRNA; replacement therapy; liver cancer; animal model
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Aravalli, R.N. Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics 2013, 3, 170-191.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top